Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11938
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLouis, Simon N Sen
dc.contributor.authorChow, Laurie T Cen
dc.contributor.authorVarghayee, Naghmehen
dc.contributor.authorRezmann, Linda Adrianaen
dc.contributor.authorFrauman, Albert Gen
dc.contributor.authorLouis, William Jen
dc.date.accessioned2015-05-16T01:34:19Z
dc.date.available2015-05-16T01:34:19Z
dc.date.issued2011-10-11en
dc.identifier.citationCancers 2011; 3(4): 3824-37en
dc.identifier.govdoc24213113en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11938en
dc.description.abstractAngiotensin II (Ang II), the main effector of the renin angiotensin system, acts upon two distinct transmembrane receptors, the Ang II type 1 and the type 2 (AT2-) receptor, to induce promotion and inhibition of ERK2 phosphorylation. The AT2-receptor, through an interaction with its putative signaling partner MTUS1/ATIP (AT2-receptor interacting protein), inhibits the mitogenic effects of EGF in prostate cancer cell lines representing both early and late stage disease. This is the first report on the expression of ATIP in normal and malignant human prostatic biopsies. The expression of ATIP and its major isoforms, ATIP1 and ATIP3, in normal prostatic cells and three prostate cancer cell lines was examined using QPCR and immunohistochemistry. Human biopsies containing benign prostatic hyperplasia (BPH), high grade prostatic intraepithelial neoplasia (HGPIN) and well, moderately and poorly differentiated prostate cancer were also examined. Overall, ATIP1 and ATIP3 mRNA expression was increased in malignant compared to normal tissues and cell lines. ATIP immunostaining was low or absent in both the basal and columnar epithelial cell layers surrounding BPH acini; however, it was observed in high concentration in neoplastic epithelial cells of HGPIN and was clearly evident in cytoplasms of malignant cells in all prostate cancer grades. ATIP immunostaining was also identified in the cytoplasms of LNCaP and PC3 prostate cancer cells. As the AT2-receptor/ATIP inhibitory signaling pathway exists in malignant cells in all grades of prostate cancer, enhancement of this pathway may be a therapeutic target even after the development of androgen-independence.en
dc.language.isoenen
dc.titleThe Expression of MTUS1/ATIP and Its Major Isoforms, ATIP1 and ATIP3, in Human Prostate Cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancersen
dc.identifier.affiliationClinical Pharmacology and Therapeutics Unit, Department of Medicine, University of Melbourne, Austin Health, Heidelberg 3084, Victoria, Australiaen
dc.identifier.doi10.3390/cancers3043824en
dc.description.pages3824-37en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24213113en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Jan 26, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.